Anticipating and retiring inherent risks in biosimilar development
The global uptake of parenteral biosimilars has been rapidly increasing, leading to an estimated compound annual growth rate of 15% through 2030.1
A key driver for biosimilar volume growth has been the expected loss of protection for originator brands which account for more than $100B in global sales.2
As a result, the market is becoming increasingly competitive putting first-to-market entrants at an advantage. It is critical for pharmaceutical companies to prevent challenges from occuring early in development.
 |
 |
 |
 |
 |
 |
 |
See how BD can help de-risk combination product development for generics and biosimilars
